arXiv:2502.13344cs.LGcs.CL2025-02KDD被引 18

用路径检索提升药物重定位与相互作用预测的准确性与可解释性

K-Paths: Reasoning over Graph Paths for Drug Repurposing and Drug Interaction Prediction

  • 基于改进的Yen算法,从生物医学知识图谱中提取多样且有意义的多跳路径
  • 零样本条件下使LLM在药物相互作用预测上F1提升最高达19.8点
  • 无需训练,可兼容大模型与图神经网络,支持可解释推理

生物医学知识图谱(KGs)包含丰富的结构化信息,对药物发现至关重要,但其复杂结构使得从大规模图谱中提取有效见解仍具挑战。现有子图检索方法多针对图神经网络(GNN),难以适配其他范式,如大语言模型(LLMs)。我们提出K-Paths,一种模型无关的检索框架,能从密集的生物医学知识图谱中提取结构化、多样且生物学意义明确的多跳路径。这些路径可预测未观测到的药物-药物和药物-疾病相互作用,包括训练时未见实体,支持归纳推理。K-Paths无需训练,采用多样性增强的Yen算法,提取查询实体间前K条无环最短路径,优先选择生物学相关且关系多样的连接。这些路径构成简洁、可解释的推理链,可直接集成至LLMs或GNNs以提升泛化能力、准确率并实现可解释推断。在基准数据集上的实验表明,K-Paths显著提升主流LLMs的零样本推理性能:Tx-Gemma 27B在相互作用严重程度预测与药物重定位任务上分别提升19.8和4.0 F1点;Llama 70B分别提升8.5和6.2点。同时,它将EmerGNN的训练效率提升90%(仅需原知识图谱10%大小),且保持预测性能。K-Paths还弥合了知识图谱与大模型之间的鸿沟,推动可扩展、可解释的科学发现。代码与提取路径已开源,作为归纳推理的基准。

原文摘要 · Abstract (English)

Biomedical knowledge graphs (KGs) encode rich, structured information critical for drug discovery tasks, but extracting meaningful insights from large-scale KGs remains challenging due to their complex structure. Existing biomedical subgraph retrieval methods are tailored for graph neural networks (GNNs), limiting compatibility with other paradigms, including large language models (LLMs). We introduce K-Paths, a model-agnostic retrieval framework that extracts structured, diverse, and biologically meaningful multi-hop paths from dense biomedical KGs. These paths enable the prediction of unobserved drug-drug and drug-disease interactions, including those involving entities not seen during training, thus supporting inductive reasoning. K-Paths is training-free and employs a diversity-aware adaptation of Yen's algorithm to extract the K shortest loopless paths between entities in a query, prioritizing biologically relevant and relationally diverse connections. These paths serve as concise, interpretable reasoning chains that can be directly integrated with LLMs or GNNs to improve generalization, accuracy, and enable explainable inference. Experiments on benchmark datasets show that K-Paths improves zero-shot reasoning across state-of-the-art LLMs. For instance, Tx-Gemma 27B improves by 19.8 and 4.0 F1 points on interaction severity prediction and drug repurposing tasks, respectively. Llama 70B achieves gains of 8.5 and 6.2 points on the same tasks. K-Paths also boosts the training efficiency of EmerGNN, a state-of-the-art GNN, by reducing the KG size by 90% while maintaining predictive performance. Beyond efficiency, K-Paths bridges the gap between KGs and LLMs, enabling scalable and explainable LLM-augmented scientific discovery. We release our code and the retrieved paths as a benchmark for inductive reasoning.

知识图谱药物重定位可解释性大模型

Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品;中文卡片由大模型生成,请以原文为准。